Thrombus Composition in Cerebral Infarctions: Study of Its Association With Plasma Biomarkers, Treatment Efficacy, Etiology and Prognosis. (COMPOCLOT)

February 3, 2026 updated by: François Delvoye

Composition du Thrombus Dans Les Infarctus cérébraux : étude du Lien Avec Avec Des Biomarqueurs Plasmatiques, l'efficacité du Traitement, l'étiologie et le Pronostic.

This study focuses on thrombi collected during mechanical thrombectomy procedures, as well as on plasma biomarkers analyzed concomitantly. The primary objective of the study is to investigate associations and correlations between, on the one hand, the composition of thrombi retrieved during thrombectomy and, on the other hand, plasma biomarkers, treatment response, etiology, and prognosis of ischemic stroke and cerebral venous thrombosis.

The secondary objectives of this study are to precisely characterize the biochemical composition of the thrombi (notably using techniques such as enzyme-linked immunosorbent assay [ELISA] following extraction of proteins contained within the thrombus), their histological structure (using standard histology with hematoxylin-eosin staining and immunohistochemistry), and their biological activity (in particular through in vitro assays assessing resistance to thrombolysis and the endothelial-adhesive or destructive properties of thrombi). Additional secondary objectives include testing new therapeutic methods for the lysis of thrombi collected by mechanical thrombectomy and establishing a link between thrombus transcriptomics and their confirmed etiology, particularly for thrombi initially described as having an embolic appearance and of undetermined etiology.

Study Overview

Status

Not yet recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

500

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Among patients treated at Liège University Hospital.

Description

Inclusion Criteria:

  • Patients aged 18 years and older
  • Presenting with cerebral infarction secondary to an arterial occlusion responsible for an ischemic stroke, or with cerebral venous thrombosis (CVT) having undergone a mechanical thrombectomy (MT) procedure
  • Managed with mechanical thrombectomy
  • Provision of free, informed, and explicit consent by the patient or their legal representative/next of kin (emergency inclusion procedure)

Exclusion Criteria:

  • Patients under legal protection measures (e.g., guardianship or curatorship)
  • Patients for whom the thrombectomy specimen cannot be retrieved or is not suitable for analysis (estimated at approximately 50% of patients undergoing MT)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Patient treated with a thrombectomy

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Diminution or increase of the NIHSS (National Institutes of Health Stroke Scale) score. The scale goes from 0 to 42, the higher, the more severe.
Time Frame: In the 24 hours after the thrombectomy
In the 24 hours after the thrombectomy

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

François Delvoye

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

February 12, 2026

Primary Completion (Estimated)

February 12, 2036

Study Completion (Estimated)

May 30, 2036

Study Registration Dates

First Submitted

January 22, 2026

First Submitted That Met QC Criteria

January 29, 2026

First Posted (Actual)

February 3, 2026

Study Record Updates

Last Update Posted (Actual)

February 5, 2026

Last Update Submitted That Met QC Criteria

February 3, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2025-286

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

Accessible upon request after publication

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Ischemic Stroke

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Japan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe